### **Overview** Alembic Pharmaceuticals Limited (Alembic) is an **integrated, research-driven generic pharmaceutical company**, founded in **1907** and headquartered in **Vadodara, Gujarat, India**. As a publicly listed entity on Indian stock exchanges, Alembic operates globally with a diversified portfolio across **Active Pharmaceutical Ingredients (APIs)**, **generic formulations**, and **branded specialty medicines**. The company leverages vertical integration, robust R&D capabilities, and FDA-approved manufacturing facilities to maintain compliance and competitiveness in regulated and emerging markets. The company serves over **80 countries**, with a strong commercial presence in the **U.S., Europe, Canada, Australia, Latin America (LATAM), the Middle East (MENA), and South Africa**. --- ### **Business Segments** Alembic’s operations are organized into three core segments: 1. **Domestic Branded Business (India)** 2. **International Generics Business (US & Rest of World – RoW)** 3. **Active Pharmaceutical Ingredients (APIs)** --- ### **Strategic Highlights (as of Nov 2025)** #### **1. Global Market Positioning & Geographic Expansion** - **India**: Ranks **21st** in the Indian formulations market with a **1.4% market share** (MAT basis, Mar 2025). - **U.S. Generics Business**: Well-established commercial presence with **167 products commercialized** as of Q1 FY26. - **Ex-US Growth**: - The **Ex-US Generics** segment achieved **21% YoY revenue growth** in Q1 FY26, driven by higher demand and product mix improvements. - **Strategic expansion** into **Chile**, **Brazil**, **UAE**, and **Mexico**, with over 100 product approvals in Chile and a growing subsidiary footprint. - **UAE** operations now include a scientific office and subsidiary to strengthen entry into MENA and European markets. - The company **sells products in over 40 countries**, with growing momentum in LATAM and RoW. --- #### **2. U.S. Generics – Strategic Pivot to Complex Generics** - **Commercialization Momentum**: - 167 products launched in the U.S. as of Q1 FY26 (4 new in the quarter). - A pipeline of **over 15 planned launches in FY26**, supported by new manufacturing facilities. - **Complex Portfolio Shift**: - Reducing reliance on **oral solid dosages (OSD)** due to **intense price erosion**. - Strategic focus on **high-value, complex generics** in **oncology, injectables, ophthalmology, dermatology, and peptides**. - **Regulatory Strength**: - All U.S. manufacturing facilities (**F1, F2, F4**) received **FDA approval without major observations**, ensuring uninterrupted supply. - As of Mar 31, 2025: **46 ANDA applications pending**, including 24 for OSD, 11 for injectables, and others in ophthalmology/dermatology. - **R&D & Filing Strategy**: - Plans to submit **over 20 new ANDAs in FY26**. - **75+ molecules** in development, with strategic emphasis on **non-OSD platforms**. - Targeting **10 high-value U.S. products** (market potential >$1 billion) with **full API integration** to capture **first-to-file, day-one-launch** advantages. --- #### **3. International Generics (Ex-US) – Growth Engine** - **Revenue Growth**: Delivered **21% YoY growth** in Q1 FY26. - **Key Regions**: - **Europe, Canada, Australia, Brazil, South Africa**: Supported by long-standing strategic partnerships. - **Chile & LATAM**: Over 100 product registrations in under two years; 40 commercialized. LATAM identified as a **high-growth, high-return region**. - **UAE/Iraq**: Subsidiary established; initial product filings submitted. - **Growth Strategy**: - **Dossier extension model** to accelerate global filings using U.S. approvals. - Expanding into **Brazil**, **Mexico**, and **Saudi Arabia** with targeted launches. - Launching over **25 new products** planned in LATAM in FY25. --- #### **4. API Business – Resilience Amid Competitive Pressures** - Historically high-margin, EBITDA-strong business. - Supplies **high-quality APIs** from FDA-approved facilities to **over 60 countries**. - **Challenges**: - **API price erosion** due to reduced pricing opacity in global markets, especially from **leaked Chinese export pricing data**. - FY25 saw temporary revenue decline, but recovery driven by **improved asset utilization & cost optimization**. - **Growth Initiatives**: - **Peptide block development** underway – expected to drive API and formulation growth. - Expansion into **oncology APIs**, **GLP-1**, and **complex peptides**. - 762 patents filed for **APIs/intermediates**, demonstrating IP strength. - **15+ products in pipeline**, with **132 Drug Master Files (DMFs)** filed by FY24. --- #### **5. Animal Health – Market Leadership & Consistent Growth** - **Segment Focus**: Livestock, poultry, and companion animals. - **Market Position**: Leader in **hematinics** and **antibiotics**. - **Flagship Brands**: *Sharkoferrol, Moxel, Xceft, Mceft*. - **Financial Performance**: Achieved **17% YoY growth** in Q1 FY26. - **Brand Portfolio** (as of Aug 2025): - **5+ brands** with annual sales > INR 300 million - **8+ brands** in INR 100–300 million - **22+ brands** in INR 20–100 million - The division achieved **21% revenue growth in FY25** and a **3-year CAGR of 24%**, driven by new product launches and tech-enabled field force expansion. --- #### **6. India Branded Business – Diversified Specialty Focus** - **Flagship division**, with strong brand recall among HCPs. - **Therapeutic Focus**: Specialty treatments in **gynecology, diabetology, GI, ophthalmology, and ortho**. - **Manufacturing**: - **Sikkim facility** for domestic branded products. - New **16.65-acre greenfield facility in Pithampur, Indore**, commissioned to reduce lead time and logistics costs. - **Market Presence**: - **191 brands** across 12 therapeutic areas. - Engages **over 233,000 prescribing doctors** via **>5,000 sales representatives**. - **4 brands** with ≥ ₹1,000 crore in annual revenue (e.g., *Azithral*, ranked in Top 300 brands). - **Growth Strategy**: Expanding focus on **lifestyle therapies** and **animal health** in underserved Tier 3–4 towns. --- #### **7. R&D & Advanced Manufacturing Capabilities** - **R&D Hubs**: Vadodara (non-oncology), Hyderabad (oncology & complex generics), and U.S. support team. - **800+ R&D professionals** focused on complex chemistry, formulations, and technology platforms. - **Key R&D Focus Areas**: - Oncology (injectables & oral) - Peptides (including GLP-1) - Ophthalmology - Dermatology - Transdermal and targeted delivery (liposomes, microspheres, nanoparticles) - **Technological Milestones**: - Developed **sterile manufacturing** for **liposomal formulations** and **microspheres**. - **In-house device manufacturing** for **pre-filled syringes, pens, cartridges**, and **auto-injectors**. - **Spray drying** technology at F2 plant for **oncology solid dispersions**. - **Peptide block** launched in FY25 to support future injectable product pipeline. --- #### **8. Recent Acquisitions & M&A** - **Utility Therapeutics Acquisition (Jul 2025)**: - Gained rights to **Pivya** (FDA-approved for **uncomplicated UTIs**) and **MEC** (in development for **complicated UTIs**). - Adds **branded specialty pipeline** in urology, enhancing Alembic’s presence in the U.S. market. - Majority-held **subsidiaries** include: - TicTwo Therapeutics Inc. (100%) - Alembic Lifesciences Inc. (100%) - **Joint Ventures & Associates**: - Incozen Therapeutics Pvt. Ltd. (50%) - Dahlia Therapeutics SA (50%) - Alembic Mami SPA (49%) - SPH Sine Alembic (44%) - Rhizen Pharmaceuticals AG (via associate chain) --- ### **Manufacturing & Operational Excellence** - **9 Manufacturing Facilities**: - **Panelav, Karkhadi, Jarod (Gujarat)**: Serve global markets (formulations & APIs). - **Sikkim**: Domestic branded formulations. - **FDA-Approved Sites**: F1 (Panelav), F2 (oncology), F3 (injectables), F4 (oral solids). - **Capacity Expansion**: - F4 plant (Jarod) approved for **OSD** – 15 products transferred; 15 more planned. - **Sustainability**: 12 MW solar plant operational with **~18–20% ROI** and <5-year payback.